Agamree (vamoxone) is the first innovative glucocorticoid approved for the treatment of Duchenne muscular dystrophy (DMD). Its global launch process has covered many countries. Understanding its launch status will help patients plan their treatment path rationally.Agamree, a vamoxone drug, is used to treat Duchenne muscular dystrophy and is now available in the United States.

International approval and price information

Agamree was developed by Santhera Pharmaceuticals of Switzerland and was first launched in Germany on January 15, 2024, and then expanded to the United States, the United Kingdom and other regions. The drug is a 40mg/mL oral suspension, 100mL per box. As the first fully approved DMD drug in the European Union, Agamree is suitable for all gene mutation types of patients aged 4 years and above, without relying on walking ability assessment.

Unlaunched status and acquisition suggestions

Agamree has not yet been approved by NMPA and is not included in medical insurance reimbursement. Domestic patients need to obtain original drugs through cross-border medical channels, but they need to bear high costs (nearly 10,000 US dollars per box) and cold chain transportation risks. Generic drugs are not yet on the market. Patients are advised to participate in clinical trials or contact rare disease organizations for assistance.

After clarifying the global accessibility of Agamree, patients need to focus on medication specifications. The following content will explain the core precautions in treatment.

Precautions for use of Agamree

Agamree improves DMD symptoms by regulating immunity and anti-inflammatory effects, but its use must strictly follow the dosage adjustment and monitoring requirements to reduce the risk of adverse reactions.

Dosage adjustment and medication specifications

The standard dose is 6 mg/kg per day (up to 300 mg), taken with meals to improve absorption. Patients with mild to moderate hepatic insufficiency need to reduce the dose to 2 mg/kg/day (up to 100 mg). When used in combination with strong CYP3A4 inhibitors (such as itraconazole), the dose should be adjusted to 4 mg/kg/day (up to 200 mg). When stopping the drug, the dose needs to be gradually reduced to avoid inducing adrenal insufficiency.

Special populations and drug storage

It is prohibited for children under 2 years old; patients with impaired liver function need to adjust the dosage individually. The drug needs to be stored upright at 20°C-25°C, refrigerated after opening (2°C-8°C) and used up within 3 months. Unopened products should avoid freezing, and transportation must be cold chain throughout the process.

Standardized medication is the basis for ensuring efficacy. The following content will list in detail the possible side effects and countermeasures during treatment.

Possible adverse reactions of Agamree

Agamree showed an adverse reaction spectrum similar to that of glucocorticoids in clinical trials, and health risks need to be reduced through early identification and intervention.

Common short-term reactions

About 37% of patients experienced Cushing-like changes (rounded face, hirsutism), and 32% experienced vomiting or diarrhea. The incidence of mental symptoms such as mood swings and insomnia is about 15%, and family members need to observe closely. Weight gain and vitamin D deficiency can be improved through dietary adjustments, and calcium and vitamin D3 supplementation is recommended.

Long-term complications and monitoring

Long-term use may cause decreased bone density (increased risk of fractures), cataracts or glaucoma (intraocular pressure needs to be tested every 6 weeks), and adrenal cortex suppression (gradually reduce the dose and stop the drug). The risk of infection increases, and timely medical attention is required if fever or respiratory symptoms occur. Regularly test blood pressure, electrolytes, and fasting blood sugar, especially for patients with a history of cardiovascular disease.

Strictly following the doctor's advice and regular follow-up visits are the key to maximizing the benefits of Agamree treatment. Patients need to record changes in symptoms after taking the drug and communicate with their doctors in a timely manner to adjust the plan. Store the drug properly to avoid high temperature or freezing that may cause it to become ineffective. Through scientific management and home care, Agamree is expected to provide DMD patients with more lasting motor function protection and improved quality of life.